Literature DB >> 7754005

Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management.

Y Hatanaka1, Y Yamashita, M Takahashi, Y Koga, R Saito, K Nakashima, J Urata, M Miyao.   

Abstract

PURPOSE: To evaluate the effect of transcatheter management of hepatocellular carcinoma (HCC) on survival.
MATERIALS AND METHODS: A prospective trial of transcatheter arterial embolization (TAE) was performed in patients with unresectable HCC. Three hundred twenty-two patients (265 men, 57 women; age range, 30-83 years) underwent TAE alone: 60 patients underwent TAE with gelatin sponge (GS) that contained anticancer agents (protocol 1); 78, TAE with GS and iodized oil mixed with anticancer agents (protocol 2); and 159, TAE with iodized oil with anticancer agents (protocol 3). A Cox proportional hazard model was used to analyze prognostic factors.
RESULTS: In the randomized group (n = 272), survival rates for protocols 1, 2, and 3 were 80.4%, 86.3%, and 65.9%, respectively, at 1 year. Findings of analysis of prognostic factors showed that extrahepatic metastases, ascites, tumor extension, and icterus were the important factors.
CONCLUSION: TAE with GS was superior to TAE without GS. Patient characteristics were important factors for survival.

Entities:  

Mesh:

Year:  1995        PMID: 7754005     DOI: 10.1148/radiology.195.3.7754005

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  19 in total

1.  Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?

Authors:  Koichiro Yamakado; Shiro Miyayama; Shozo Hirota; Kimiyoshi Mizunuma; Kenji Nakamura; Yoshitaka Inaba; Akihiro Maeda; Kunihiro Matsuo; Norifumi Nishida; Takeshi Aramaki; Hiroshi Anai; Shinichi Koura; Shigeo Oikawa; Ken Watanabe; Taku Yasumoto; Kinya Furuichi; Masato Yamaguchi
Journal:  Jpn J Radiol       Date:  2012-05-30       Impact factor: 2.374

Review 2.  [Therapy of hepatitis C].

Authors:  D M Alscher; J C Bode
Journal:  Med Klin (Munich)       Date:  1997-03-15

3.  [Transarterial ablation of hepatocellular carcinoma. Status and developments].

Authors:  B A Radeleff; U Stampfl; C M Sommer; N Bellemann; K Hoffmann; T Ganten; R Ehehalt; H U Kauczor
Journal:  Radiologe       Date:  2012-01       Impact factor: 0.635

4.  Transcatheter arterial embolization-induced bilious pleuritis in a patient with hepatocellular carcinoma.

Authors:  T Ichikawa; T Yamada; H Takagi; T Abe; H Ito; S Sakurai; T Nagamine; M Mori
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

5.  Evaluation of transarterial chemoembolization combined with percutaneous ethanol ablation for large hepatocellular carcinoma.

Authors:  Fei Gao; Yang-Kui Gu; Wei-Jun Fan; Liang Zhang; Jin-Hua Huang
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

6.  Transarterial chemoembolization in patients with hepatocellular carcinoma: predictors of survival.

Authors:  Summit Sawhney; Aldo J Montano-Loza; Peter Salat; Mairin McCarthy; Norman Kneteman; Judith Meza-Junco; Richard Owen
Journal:  Can J Gastroenterol       Date:  2011-08       Impact factor: 3.522

7.  [Transarterial ablative therapy of hepatocellular carcinoma].

Authors:  A H Mahnken
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

8.  Future perspectives on the treatment of hepatocellular carcinoma with cisplatin.

Authors:  Toru Ishikawa
Journal:  World J Hepatol       Date:  2009-10-31

Review 9.  Localized hepatocellular carcinoma: therapeutic options.

Authors:  A Ribeiro; D M Nagorney; G J Gores
Journal:  Curr Gastroenterol Rep       Date:  2000-02

10.  Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China.

Authors:  Ming Shi; Ji-An Chen; Xiao-Jun Lin; Rong-Ping Guo; Yun-Fei Yuan; Min-Shan Chen; Ya-Qi Zhang; Jin-Qing Li
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.